Sun Pharmaceutical Industries' generic Namenda ANDA: USFDA grants tentative approval

NewsGuard 100/100 Score
Apr 12 2010

Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Forest Laboratories, Inc.'s Namenda 5 mg and 10 mg tablets.

These generic Memantine tablets are equivalent to Forest Laboratories, Inc's Namenda® tablets and includes two strengths: 5 mg and 10 mg. These strengths of Memantine have a combined annual sale of approximately $1.2 billion in the US.

Memantine tablets are indicated for the treatment of moderate to severe Alzheimer's Disease.

Source:

 Sun Pharmaceutical Industries Ltd.

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , ,

Comments (0)

Suggested Reading

LabVantage celebrates customer success with record number of software deployments in FY 2024
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
Lancet Commission predicts sharp increase in global prostate cancer cases
The Lancet Breast Cancer Commission: Tackling inequalities, hidden costs, and empowering patients
Study highlights global fertility decline and its implications for the future
Common HIV drugs linked to reduced Alzheimer's disease risk
Recycled food waste may be contaminated with pharmaceutical residues, research reveals
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Supply chain assessment and management, optimizing pharmaceutical supply chains